CAS |
No.127-07-1 |
中文名称 |
羟基脲(10mM in DMSO,无菌) |
英文名称 |
Hydroxyurea(10mM in DMSO,Sterile) |
分子式 |
CH4N2O2 |
分子量 |
76.05 |
溶解性 |
请根据自己的实验要求使用。 |
外观(性状) |
无菌溶液 |
储存条件 |
Stroe at -20℃,6 months. |
靶点 |
DNA/RNA Synthesis |
通路 |
Cell Cycle;DNA Damage/DNA Repair |
背景说明 |
Hydroxyurea通过抑制核糖核苷酸还原酶抑制DNA合成的细胞凋亡诱导剂。 |
生物活性 |
Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase. Hydroxyurea shows anti-orthopoxvirus activity.[1-5] |
In Vitro |
Hydroxyurea 用于许多骨髓增生性疾病、肿瘤、HIV 和非血液疾病的研究[1]。用 30 μM Hydroxyurea 处理原代培养物中的细胞 96 小时可显著增加部分 HbF 含量。Gγ:Aγ-珠蛋白 mRNA 在体外诱导 0.30 至 8 倍. Hydroxyurea 已被证明可以阻断静止的外周血单核细胞和巨噬细胞中的 HIV-1 逆转录和/或复制[2][3]。 |
In Vivo |
Hydroxyurea 疗法在 17 周内持续降低 WBC 和 ANC,但贫血没有改善。与赋形剂处理的镰状细胞小鼠相比,50 mg/kg 的 Hydroxyurea 可降低白细胞计数和中性粒细胞绝对计数,并且贫血没有改善[4]。 |
动物实验 |
Mice: To determine whether hydroxyurea would improve anemia and/or prevent or diminish the development of organ damage in the absence of HbF induction, hydroxyurea, at doses of 25 mg/kg, 50 mg/kg, and 100 mg/kg, or vehicle is administered five days per week to SCD mice[4]. |
数据来源文献 |
[1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31. [2]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92. [3]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7. [4]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603. [5]. M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 1986 Nov;60(2):506-14. |
规格 |
0.1ml 0.3ml 0.5ml 1ml 1.5ml |
单位 |
瓶 |